tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2020-98-6-60-69tiblj-1437Research ArticleОБЗОРREVIEWСовременные подходы к поиску активных препаратов, схем и режимов химиотерапии туберкулезаContemporary approaches to the search for active drugs and chemotherapy regimens for tuberculosis treatmentЛуговкинаТ. К.LugovkinаT. K.

Луговкина Татьяна Константиновна, доктор медицинских наук, ведущий научный сотрудник научно-клинического отдела, врач ‒ клинический фармаколог.

620000, г. Екатеринбург, ул. 22-го Партсъезда, д. 50.

Тел.: 8 (343) 333-44-33.

Tatiana K. Lugovkina, Doctor of Medical Sciences, Leading Researcher of Research Clinical Department, Clinical Pharmacologist.

50, XXII Parts"ezda St., Yekaterinburg, 620000.

Phone: +7 (343) 333-44-33.

lugovkina@gmail.comСкорняковС. Н.SkornyakovS. N.

Скорняков Сергей Николаевич, доктор медицинских наук, профессор, руководитель научно-клинического отдела, главный внештатный фтизиатр УрФО.

620000, г. Екатеринбург, ул. 22-го Партсъезда, д. 50.

Тел.: 8 (343) 333-44-33.

Sergey N. Skornyakov, Doctor of Medical Sciences, Professor, Head of Research Clinical Department, Chief TB Expert of the Ural Federal District.

50, XXII Parts"ezda St., Yekaterinburg, 620000.

Phone: +7 (343) 333-44-33.

sns@urniif.ruКильдюшеваЕ. И.KildyushevаE. I.

Кильдюшева Елена Ивановна, кандидат медицинских наук, заведующая отделением для лечения больных туберкулезом легких с МЛУ.

620000, г. Екатеринбург, ул. 22-го Партсъезда, д. 50.

Тел.: 8 (343) 333-44-33.

Elena I. Kildyusheva, Candidate of Medical Sciences, Head of MDR Pulmonary Tuberculosis Department.

50, XXII Parts"ezda St., Yekaterinburg, 620000.

Phone: +7 (343) 333-44-33.

kildusheva@urniif.ruЕгоровЕ. А.EgorovE. A.

Егоров Евгений Анатольевич, кандидат медицинских наук, заместитель директора по медицинской части, старший научный сотрудник.

620000, г. Екатеринбург, ул. 22-го Партсъезда, д. 50.

Тел.: 8 (343) 333-44-33.

Evgeniy A. Egorov, Candidate of Medical Sciences, Deputy Director for Medical Activities, Senior Researcher.

50, XXII Parts"ezda St., Yekaterinburg, 620000.

Phone: +7 (343) 333-44-33.

egorovea@urniif.ruУральский научно-исследовательский институт фтизиопульмонологии ‒ филиал ФГБУ «Научный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияUral Phthisiopulmonology Research Institute, National Medical Research Center of Phthisiopulmonology and Infectious DiseasesRussian Federation2020100720209866069Copyright © Луговкина Т.К., Скорняков С.Н., Кильдюшева Е.И., Егоров Е.А., 20202020Луговкина Т.К., Скорняков С.Н., Кильдюшева Е.И., Егоров Е.А.Lugovkinа T.K., Skornyakov S.N., Kildyushevа E.I., Egorov E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1437

Проведен анализ научных публикаций (37 источников) в области фтизиатрии, клинической фармакологии антимикробных препаратов, лабораторных методов оценки эффективности и безопасности различных схем и режимов химиотерапии туберкулеза, обусловленного резистентными штаммами M. tuberculosis.

Представлена информация о перспективах расширения линейки антимикробных препаратов для лечения туберкулеза, обусловленного резистентными штаммами M. tuberculosis, новых подходах к изучению и оценке эффективности лекарственных воздействий на этапе доклинических исследований с применением модели in vitro HFS-ТВ.

The article analyzes scientific publications (37 articles) devoted to phthisiology, clinical pharmacology of antimicrobial agents, laboratory methods for evaluating the effectiveness and safety of various regimens of tuberculosis chemotherapy caused by resistant strains of M. tuberculosis.

It tells about prospects for expanding the line of antimicrobial agents for treatment of tuberculosis caused by resistant strains of M. tuberculosis, new approaches to the study and evaluation of the effectiveness of the drug at the stage of preclinical trials using the in vitro HFS-TV model.

фтизиатрияантибиотикорезистентностьM. Tuberculosisphthisiologyantibiotic resistanceM. tuberculosisReferencesГолубчиков П. Н., Крук Е. А., Мишустин С. П., Петренко Т. И., Кудлай Д. А. Опыт лечения больных туберкулезом c широкой лекарственной устойчивостью возбудителя, в том числе с длительным применением бедаквилина, в Томской области: непосредственные и отдаленные результаты // Туб. и болезни легких. – 2019. – Т. 97, № 8. – С. 38-45.Golubchikov P.N., Kruk E.А., Mishustin S.P., Petrenko T.I., Kudlay D.А. Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 8, pp. 38-45. (In Russ.)Жукова Е. М., Вохминова Л. Г., Кудлай Д. А. Влияние современной химиотерапии туберкулеза с МЛУ/ШЛУ на изменение у больных интервала QT на ЭКГ // Туб. и болезни легких. – 2019. – Т. 97, № 11. – С. 19-22. http://doi.org/10.21292/2075-1230-2019-97-11-19-22.Zhukova E.M., Vokhminova L.G., Kudlay D.А. The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 11, pp. 19-22. (In Russ.) http://doi.org/10.21292/2075-1230-2019-97-11-19-22.Кильдюшева Е. И., Егоров Е. А., Скорняков С. Н., Медвинский И. Д., Залетаева Г. Е., Подгаева В. А., Луговкина Т. К., Охтяркина В. В., Кравченко М. А., Фадина О. В., Щипунов С. В., Гущин А. С. Клиническая результативность новых лекарственных препаратов в схемах лечения туберкулеза с множественной и широкой лекарственной устойчивостью возбудителя // РМЖ. ‒ 2017. ‒ № 18. ‒ Р. 1288-1295.Kildyusheva E.I., Egorov E.А., Skornyakov S.N., Medvinskiy I.D., Zaletaeva G.E., Podgaeva V.А., Lugovkina T.K., Okhtyarkina V.V., Kravchenko M.А., Fadina O.V., Schipunov S.V., Guschin А.S. The clinical effectiveness of new drugs in treatment regimens of multiple and extensive drug resistant tuberculosis. RMJ, 2017, no. 18, pp. 1288-1295.(In Russ.)Тихонова Л. Ю., Соколова В. В., Тарасюк И. А., Екименко А. М., Черенкова М. А., Кудлай Д. А. Опыт применения препарата Бедаквилин у больных туберкулезом с множественной лекарственной устойчивостью возбудителя в Амурской области // Туб. и болезни легких. – 2018. – Т. 96, № 6. – С. 45-50.Tikhonova L.Yu., Sokolova V.V., Tarasyuk I.А., Ekimenko А.M., Cherenkova M.А., Kudlay D.А. Experience of treatment of multiple drug resistant tuberculosis patients with bedaquiline in Amur Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 6, pp. 45-50. (In Russ.)Andries K., Verhasselt P., Guillemont J. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis // Science. ‒ 2005. ‒ № 307(5707). ‒ Р. 223-227.Andries K., Verhasselt P., Guillemont J. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, no. 307 (5707), pp. 223-227.Andries K., Villellas C., Coeck N., Thys K., Gevers T., Vranckx L., Lounis N., de Jong B. C., Koul A. Acquired resistance of Mycobacterium tuberculosis to bedaquiline // PLoS One. ‒ 2014. ‒ № 9. ‒ Р. e102135.Andries K., Villellas C., Coeck N., Thys K., Gevers T., Vranckx L., Lounis N., de Jong B. C., Koul A. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One, 2014, no. 9, pp. e102135.Beckert P., Hillemann D., Kohl T. A., Kalinowski J., Richter E., Niemann S., Feuerriegel S. rplC T460C identified as a dominant mutation in linezolid resistant Mycobacterium tuberculosis strains // Antimicrob. Agents Chemother. ‒ 2012. ‒ № 56. ‒ Р. е2743-e2745.Beckert P., Hillemann D., Kohl T.A., Kalinowski J., Richter E., Niemann S., Feuerriegel S. rplC T460C identified as a dominant mutation in linezolid resistant Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother., 2012, no. 56, pp. е2743-e2745.Blaser J., Stone B. B., Groner M. C., Zinner S. H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance // Antimicrob. Agents Chemother. ‒ 1987. ‒ № 31. ‒ Р. 1054-1060.Blaser J., Stone B.B., Groner M.C., Zinner S.H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother., 1987, no. 31, pp. 1054-1060.Brown A. N., Drusano J. L., Adams J. R., Rodriquez J., Jambunathan K., Baluya D. L., Brown D. L., Kwara A., Mirsalis J. C., Hafner R., Louie A. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy // MBio. ‒ 2015. ‒ Vol. 6, № 6. ‒ Р. e01741-15. doi:10.1128.Brown A.N., Drusano J.L., Adams J.R., Rodriquez J., Jambunathan K., Baluya D.L., Brown D.L., Kwara A., Mirsalis J.C., Hafner R., Louie A. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy. MBio., 2015, vol. 6, no. 6, pp. e01741-15. doi:10.1128.Caminero J. A. Guidelines for clinical and operational management of drug resistant tuberculosis. Paris, France: International Union Against Tuberculosis and Lung Disease; 2013.Caminero J.A. Guidelines for clinical and operational management of drug resistant tuberculosis. Paris, France, International Union Against Tuberculosis and Lung Disease; 2013.Caminero J. A., Matteelli A., Lange C. Treatment of TB. In: Lange C., Migliori G. B., editors. Tuberculosis (ERS Monograph). Sheffield: European Respiratory Society. ‒ 2012. ‒ Р. 154-166.Caminero J.A., Matteelli A., Lange C. Treatment of TB. In: Lange C., Migliori G.B., editors. Tuberculosis (ERS Monograph). Sheffield, European Respiratory Society. 2012, pp. 154-166.Caminero J. A., Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence // Eur. Respir. J. ‒ 2015. ‒ № 46. ‒ Р. 887-893.Caminero J.A., Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence. Eur. Respir. J., 2015, no. 46, pp. 887-893.Cavaleri M., Manolis E. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience // Clinical Infectious Diseases. ‒ 2015. ‒ № 61, Issue suppl. 1, 15 August: S1-S4, https://doi.org/10.1093/cid/civ484.Cavaleri M., Manolis E. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience. Clinical Infection Diseases, 2015, no. 61, Issue suppl. 1, 15 August: S1-S4, https://doi.org/10.1093/cid/civ484.Chang K. C., Nuermberger E., Sotgiu G., Leung C. C. New drugs and regimens for tuberculosis // Respirology. ‒ 2018. ‒ Vol. 11, № 23. ‒ Р. 978-990.Chang K.C., Nuermberger E., Sotgiu G., Leung C.C. New drugs and regimens for tuberculosis. Respirology, 2018, vol. 11, no. 23, pp. 978-990.Deshpande D., Srivastava S., Jotam G. Pasipanodya S. J., Bush E., Nuermberger S., Gumbo T. Linezolid for infants and toddlers with disseminated tuberculosis: first steps // Clinical Infectious Diseases. ‒ 2016. ‒ Vol. 63, № 11. Issue suppl. 3. ‒ Р. S80-S87, https://doi.org/10.1093/cid/ciw482.Deshpande D., Srivastava S., Jotam G. Pasipanodya S.J., Bush E., Nuermberger S., Gumbo T. Linezolid for infants and toddlers with disseminated tuberculosis: first steps. Clinical Infection Diseases, 2016, vol. 63, no. 11, Issue suppl. 3, pp. S80-S87, https://doi.org/10.1093/cid/ciw482.Deshpande D., Srivastava S., Chapagain M., Magombedze G., Martin K. R., Cirrincione K. N., Lee P. S., Koeuth T., Dheda K., Gumbo T. Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis // Sci Adv. ‒ 2017. ‒ Vol. 3, № 8. ‒ Р. e1701102. doi: 10.1126/sciadv.1701102. eCollection 2017 Aug.Deshpande D., Srivastava S., Chapagain M., Magombedze G., Martin K.R., Cirrincione K.N., Lee P.S., Koeuth T., Dheda K., Gumbo T. Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis. Sci Adv., 2017, vol. 3, no. 8, pp. e1701102. doi: 10.1126/sciadv.1701102. eCollection 2017 Aug.Dietze R., Hadad D. J., McGee B., Molino L. P., Maciel E. L., Peloquin C. A., Johnson D. F., Debanne S. M., Eisenach K., Boom W. H., Palaci M., Johnson J. L. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis // Am. J. Respir. Crit. Care Med. ‒ 2008. ‒ № 178. ‒ Р. 1180-1185.Dietze R., Hadad D.J., McGee B., Molino L.P., Maciel E.L., Peloquin C.A., Johnson D.F., Debanne S.M., Eisenach K., Boom W.H., Palaci M., Johnson J.L. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med., 2008, no. 178, pp. 1180-1185.Guy C. S., Gibson M. I., Fullam E. Targeting extracellular glycans: tuning multimeric boronic acids for pathogen-selective killing of Mycobacterium tuberculosis // Chem. Sci. ‒ 2019. ‒ Vol. 10, № 23. ‒ Р. 5935-5942.Guy C.S., Gibson M.I., Fullam E. Targeting extracellular glycans: tuning multimeric boronic acids for pathogen-selective killing of Mycobacterium tuberculosis. Chem. Sci., 2019, vol. 10, no. 23, pp. 5935-5942.Harmanjit S., Navreet Kaur N., Nipunjot G. Bedaquiline: a new weapon against MDR and XDR-TB // Int. J. Basic Clin. Pharmacol. ‒ 2013. ‒ Vol. 2, № 2. ‒ Р. 96-102.Harmanjit S., Navreet Kaur N., Nipunjot G. Bedaquiline: a new weapon against MDR and XDR-TB. Int. J. Basic Clin. Pharmacol., 2013, vol. 2, no. 2, pp. 96-102.Hillemann D., Rüsch-Gerdes S., Richter E. In vitro-selected linezolid resistant Mycobacterium tuberculosis mutants // Antimicrob. Agents Chemother. ‒ 2008. ‒ № 2452. ‒ Р. е800-e801.Hillemann D., Rüsch-Gerdes S., Richter E. In vitro-selected linezolid resistant Mycobacterium tuberculosis mutants. Antimicrob. Agents Chemother., 2008, no. 2452, pp. е800-e801.Huitric E., Verhasselt P., Koul A., Andries K., Hoffner S., Andersson D. I. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor // Antimicrob. Agents Chemother. ‒ 2010. ‒ № 54. ‒ Р. е1022-e1028.Huitric E., Verhasselt P., Koul A., Andries K., Hoffner S., Andersson D.I. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother., 2010, no. 54, pp. е1022-e1028.Ippolito J. A., Kanyo Z. F., Wang D., Franceschi F. J., Moore P. B., Steitz T. A., Duffy E. M. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit // J. Med. Chem. ‒ 2008. ‒ № 51. ‒ Р. 3353-3356.Ippolito J.A., Kanyo Z.F., Wang D., Franceschi F.J., Moore P.B., Steitz T.A., Duffy E.M. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem., 2008, no. 51, pp. 3353-3356.Islam M. M. et al. Drug resistance mechanisms and novel drug targets for tuberculosis therapy. Review // J. Genetics and Genomics. ‒ 2017. ‒ № 44. ‒ Р. е21-e37.Islam M.M. et al. Drug resistance mechanisms and novel drug targets for tuberculosis therapy. Review J. Genetics and Genomics, 2017, no. 44, pp. е21-e37.Lee M., Lee J., Carroll M. W., Choi H., Min S., Song T., Via L. E., Goldfeder L. C., Kang E., Jin B., Park H., Kwak H., Kim H., Jeon H.-S., Jeong I., Joh J. S., Chen R. Y., Olivier K. N., Shaw P. A., Follmann D., Song S. D., Lee J.-K., Lee D., Kim C. T., Dartois V., Park S.-K., Cho S.-N., Barry C. E. Linezolid for treatment of chronic extensively drug-resistant tuberculosis // N. Engl. J. Med. ‒ 2012. ‒ № 367. ‒ Р. 1508-1518.Lee M., Lee J., Carroll M.W., Choi H., Min S., Song T., Via L. E., Goldfeder L.C., Kang E., Jin B., Park H., Kwak H., Kim H., Jeon H.-S., Jeong I., Joh J.S., Chen R.Y., Olivier K.N., Shaw P.A., Follmann D., Song S.D., Lee J.-K., Lee D., Kim C.T., Dartois V., Park S.K., Cho S.-N., Barry C.E. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med., 2012, no. 367, pp. 1508-1518.Makafe G. G. et al. Oxazolidinone resistance in Mycobacterium tuberculosis: what is the role of cys154Arg mutation in the ribosomal protein L3 // Antimicrob. Agents Chemother. ‒ 2016. ‒ № 60. ‒ Р. 3202-3206.Makafe G.G. et al. Oxazolidinone resistance in Mycobacterium tuberculosis: what is the role of cys154Arg mutation in the ribosomal protein L3. Antimicrob. Agents Chemother., 2016, no. 60, pp. 3202-3206.Matteelli A., Carvalho A. C. C., Dooley K. E. et al. TMC207: the first compound of a new class of potent anti-tuberculosis drugs // Future Microbiol. ‒ 2010. ‒ Vol. 5, № 6. ‒ Р. 849-858.Matteelli A., Carvalho A.C.C., Dooley K.E. et al. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol., 2010, vol. 5, no. 6, pp. 849-858.Migliori G. B. et al. TBNET Study Group. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis // Eur. Respir. J. ‒ 2009. ‒ № 34. ‒ Р. 387-393.Migliori G.B. et al. TBNET Study Group. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur. Respir. J., 2009, no. 34, pp. 387-393.Nuermberger E. Evolving strategies for dose optimization of linezolid for treatment of tuberculosis // Int. J. Tuberc. Lung Dis. ‒ 2016. ‒ Vol. 20, № 12. ‒ Р. 48-51. doi: 10.5588/ijtld.16.0113.Nuermberger E. Evolving strategies for dose optimization of linezolid for treatment of tuberculosis. Int. J. Tuberc. Lung Dis., 2016, vol. 20, no. 12, pp. 48-51. doi: 10.5588/ijtld.16.0113.Patel U., Yan Y. P., Hobbs F. W. Jr, Kaczmarczyk J., Slee A. M., Pompliano D. L., Kurilla M. G., Bobkova E. V. Oxazolidinones mechanism of action: inhibition of the first peptide bond formation // J. Biol. Chem. ‒ 2001. ‒ Vol. 276. ‒ Р. 37199-37205.Patel U., Yan Y.P., Hobbs F.W.Jr, Kaczmarczyk J., Slee A.M., Pompliano D.L., Kurilla M.G., Bobkova E.V. Oxazolidinones mechanism of action: inhibition of the first peptide bond formation. J. Biol. Chem., 2001, vol. 276, pp. 37199-37205.Petrella S., Cambau E., Chauffour A., Andries K., Jarlier V., Sougakoff W. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria // Antimicrob. Agents Chemother. ‒ 2006. ‒ Vol. 50. ‒ Р. 2853-2856.Petrella S., Cambau E., Chauffour A., Andries K., Jarlier V., Sougakoff W. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob. Agents Chemother., 2006, vol. 50, pp. 2853-2856.Sotgiu G., Centis R., D'Ambrosio L., Alffenaar J. W., Anger H. A., Caminero J. A., Castiglia P., De Lorenzo S., Ferrara G., Koh W. J., Schecter G. F., Shim T. S., Singla R., Skrahina A., Spanevello A., Udwadia Z. F., Villar M., Zampogna E., Zellweger J. P., Zumla A., Migliori G. B. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis // Eur. Respir. J. ‒ 2012. ‒ № 40. ‒ Р. 1430-1442.Sotgiu G., Centis R., D'Ambrosio L., Alffenaar J.W., Anger H.A., Caminero J.A., Castiglia P., De Lorenzo S., Ferrara G., Koh W.J., Schecter G.F., Shim T.S., Singla R., Skrahina A., Spanevello A., Udwadia Z.F., Villar M., Zampogna E., Zellweger J.P., Zumla A., Migliori G.B. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J., 2012, no. 40, pp. 1430-1442.Sotgiu G., Pontali E., Migliori G. B. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios // Eur. Respir. J. ‒ 2015. ‒ № 45. ‒ Р. 25-29.Sotgiu G., Pontali E., Migliori G.B. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur. Respir. J., 2015, no. 45, pp. 25-29.Tassoni R., Blok A., Pannu N. S., Ubbink M. New conformations of acylation adducts of inhibitors of β-lactamase from Mycobacterium tuberculosis // Biochemistry. ‒ 2019. ‒ Vol. 58, № 7. ‒ Р. 997-1009. DOI: 10.1021/acs.biochem.8b01085.Tassoni R., Blok A., Pannu N.S., Ubbink M. New conformations of acylation adducts of inhibitors of β-lactamase from Mycobacterium tuberculosis. Biochemistry, 2019, vol. 58, no. 7, pp. 997-1009. doi: 10.1021/acs.biochem.8b01085.Tiberi S. et al. Classifying new anti-tuberculosis drugs: rationale and future Perspectives // Internat. J. Infect. Dis. ‒ 2017. ‒ № 56. ‒ Р. 181-184.Tiberi S. et al. Classifying new anti-tuberculosis drugs: rationale and future Perspectives. Internat. J. Infect. Dis., 2017, no. 56, pp. 181-184.Wallis R. S., Dawson R., Friedrich S. O., Venter A., Paige D., Zhu T., Silvia A., Gobey J., Ellery C., Zhang Y., Eisenach K., Miller P., Diacon A. H. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis // PLoSOne. ‒ 2014. ‒ Vol. 9, № 4. ‒ Р. e94462. doi: 10.1371/journal.pone.0094462. eCollection 2014.Wallis R.S., Dawson R., Friedrich S.O., Venter A., Paige D., Zhu T., Silvia A., Gobey J., Ellery C., Zhang Y., Eisenach K., Miller P., Diacon A.H. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoSOne, 2014, vol. 9, no. 4, pp. e94462. doi: 10.1371/journal.pone.0094462. eCollection 2014.World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/ 2014.11. Geneva: WHO; 2014.World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva, WHO, 2014.Zhang M., Sala C., Dhar N., Vocat A., Sambandamurthy V. K., Sharma S., Marriner G., Balasubramanian V., Cole S. T. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis // Antimicrob. Agents Chemother. ‒ 2014. ‒ Vol. 58, № 6. ‒ Р. 3217-3223.Zhang M., Sala C., Dhar N., Vocat A., Sambandamurthy V.K., Sharma S., Marriner G., Balasubramanian V., Cole S.T. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2014, vol. 58, no. 6, pp. 3217-3223.

The authors declare that there are no conflicts of interest present.